Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
nanoliposomal irinotecan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head & Neck Cancer
1 trial -
nanoparticle albumin-bound paclitaxel/carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
nedaplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Central Nervous System Tumors
1 trial -
neoadjuvant anti-PD-1
Shanghai Chest Hospital
Esophageal Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-mutant Non-Small Cell Lung Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Neoplasms
3 trials -
nilotinib
United Therapeutics Europe Ltd
Mucosal Lentiginous Melanoma
1 trial -
nivolumab
Bristol-Myers Squibb
Neoplasms by Site
1 trial -
nivolumab, ipilimumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
oncolytic adenovirus expressing GMCSF
CG Oncology
Bladder Cancer
1 trial -
ondansetron
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma (HCC)
1 trial -
online adaptive radiotherapy
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
orelabrutinib combined with rituximab regimen
The First People's Hospital of Lianyungang
Marginal Zone Lymphoma(MZL)
1 trial -
osimertinib
AstraZeneca
Carcinoma
1 trial -
osimertinib mesylate tablets and anlotinib hydrochloride capsules
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
oxaliplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stomach Neoplasms
1 trial -
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia
2 trials -
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
United Therapeutics Europe Ltd
Anatomic Stage I Breast Cancer AJCC v8
1 trial -
paclitaxel/carboplatin/lapatinib
Hospital Authority, Hong Kong
ErbB2-Positive Stage I-III Breast Cancer
1 trial -
palifosfamide
Alaunos Therapeutics
Adult Central Nervous System Germ Cell Tumor
1 trial -
pazopanib (GW786034)
GlaxoSmithKline
Neoplasms, Uterine Cervix
1 trial -
pazopanib (GW786034) 400 mg
GlaxoSmithKline
Neoplasms, Breast
1 trial -
pegcrisantaspase
Jazz Pharmaceuticals Ireland Limited
Acute Lymphoblastic Leukemia
1 trial -
pembrolizumab
The First People's Hospital of Lianyungang
Advanced Non-squamous Non-small-cell Lung Cancer
1 trial -
pembrolizumab
Hospital Authority, Hong Kong
Locally Recurrent Cancer
1 trial -
pembrolizumab
The University of Hong Kong
T-Cell Lymphoma
1 trial -
pemetrexed
United Therapeutics Europe Ltd
Lung Cancer
1 trial -
pepinemab + pembrolizumab
VACCINEX, INC.
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
1 trial -
pharmorubicin or pirarubicin
The First People's Hospital of Lianyungang
Upper Tract Urothelial Carcinoma
1 trial -
ponatinib - Phase 1
Takeda
Chronic Myeloid Leukemia (CML)
1 trial -
pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy
The First People's Hospital of Lianyungang
HER2-positive Breast Cancer
1 trial -
radiation therapy
Children's Hospital of Fudan University
Brain Tumor
1 trial -
raltitrexed combined with apatinib
Chinese PLA General Hospital
Colorectal Cancer
1 trial -
recombinant human Angiostatin protein
CASI Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
recombinant human endostatin
Peking University Third Hospital
Melanoma
1 trial -
remicade (anti tumor necrosis factor inhibitor)
Hospital Authority, Hong Kong
Takayasu's Arteritis
1 trial -
rezatapopt
PMV Pharmaceuticals
Advanced Solid Tumor
1 trial -
rituximab
United Therapeutics Europe Ltd
Lymphoma
1 trial -
self-expandable 125I radioactive seeds-loaded-stent
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocellular Carcinoma
1 trial -
silevertinib (BDTX-1535) monotherapy
Blackmores Limited
Non-Small Cell Lung Cancer
1 trial -
sintilimab
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
sintilimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
sintiliman plus LDRT
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
ssCART-19
The First People's Hospital of Lianyungang
Relapsed or Refractory Acute Lymphoblastic Leukemia
1 trial -
ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia, Adult B-Cell
1 trial -
sunitinib added to FOLFIRI
BRIGHT MINDS BIOSCIENCES INC.
Metastatic Colorectal Cancer
1 trial -
surufatinib + fulvestrant + chidamide
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
temozolomide
Universal Integrated
Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.